ArticleThe Lancet. Oncology2024

Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.

Alex K Bryant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.